Ipsalazide

SKU: orb1706163

Description

Ipsalazide is a salicylazosulfapyridine derivative developed as a research tool for investigating inflammatory bowel disease (IBD). It serves as a molecular probe for in vitro and in vivo studies exploring novel therapeutic mechanisms and anti-inflammatory pathways in colitis models.

Research Area

Cell Biology

Key Properties

• CAS Number: 82101-17-5
• MW: 387.25
• Purity: 99.43% (May vary between batches)
• Formula: C₁₆H₁₁N₃Na₂O₆
• SMILES: O=C(C1=CC(N=NC2=CC=C(C(NCC([O-])=O)=O)C=C2)=CC=C1O)[O-].[Na+].[Na+]
• Target: Autophagy

Bioactivity

• In Vivo:
  Within 7 days of a single oral dose of ipsalazide (4 g/kg in mice or 2 g/kg in rats), no deaths or visible abnormalities occurred. At postmortem, no abnormalities were observed. The carrier molecule of ipsalazide (ABG) is readily absorbed, with nearly half of the dose appearing in the urine. However, approximately 40% of the ABG was not recovered, and it is possible that this has undergone further metabolism, resulting in the loss of the aromatic amine function, which is the basis for the colorimetric measurement of ABG.
  Read more...
• In Vitro:
  Ipsalazide is designed with the replacement of the sulfapyridine of sulfasalazine by carrier molecules, aiming to mitigate side effects. Sulfasalazine exerts beneficial effects in colitis by releasing 5-aminosalicylic acid in the colon, but its use can be limited by side effects.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Autophagy, Ipsalazide

Compound Identifiers

PubChem CID

135666516